Abstract:Several studies have demonstrated the advantages of heterodimers over their corresponding monomers due to the multivalency effect. This effect leads to an increased number of effective targeted receptors and, consequently, improved tumor uptake. Fibroblast activation protein (FAP) and integrin αvβ3 are found to be overexpressed in different components of the tumor microenvironment. In our pursuit of enhancing tumor uptake and retention, we designed and developed a novel peptidic heterodimer that synergistically targets both FAP and integrin αvβ3. FAP-RGD was synthesized from FAP-2286 and c(RGDfK) through a multi-step organic synthesis. The dual receptor binding property of 68Ga-FAP-RGD was investigated by cell uptake and competitive binding assays. Preclinical pharmacokinetics were determined in HT1080-FAP and U87MG tumor models using micro-positron emission tomography/computed tomography (micro-PET/CT) and biodistribution studies. The antitumor efficacy of 177Lu-FAP-RGD was assessed in U87MG tumor models. The radiation exposure and clinical diagnostic performance of 68 Ga-FAP-RGD were evaluated in healthy volunteers and cancer patients. Bi-specific radiotracer 68Ga-FAP-RGD exhibited high binding affinity for both FAP and integrin αvβ3. In comparison to 68Ga-FAP-2286 and 68Ga-RGDfK, 68Ga-FAP-RGD displayed enhanced tumor uptake and longer tumor retention time in preclinical models. 177Lu-FAP-RGD could efficiently suppress the growth of U87MG tumor in vivo when applied at an activity of 18.5 and 29.6 MBq. The effective dose of 68Ga-FAP-RGD was 1.06 × 10−2 mSv/MBq. 68Ga-FAP-RGD demonstrated low background activity and stable accumulation in most neoplastic lesions up to 3 h. Taking the advantages of multivalency effect, the bi-specific radiotracer 68Ga-FAP-RGD showed superior tumor uptake and retention compared to its corresponding monomers. Preclinical studies with 68Ga- or 177Lu-labeled FAP-RGD showed favorable image contrast and effective antitumor responses. Despite the excellent performance of 68Ga-FAP-RGD in clinical diagnosis, experimental efforts are currently underway to optimize the structure of FAP-RGD to increase its potential for clinical application in endoradiotherapy.

The enhancement effect of internalization RGD motif on the 18F-FDG uptake of 4T1 breast cancer in mice

Studies on distribution and imaging of 131I-labelled RGD peptide in mice bearing tumors

Tumor-penetrating peptide internalizing RGD enhances radiotherapy efficacy through reducing tumor hypoxia

131)I Labeling and Bioactivity Evaluation of a Novel RGD Dimer Targeted to Integrin Αvβ3 Receptor

Evaluation of 68 Ga-labeled iNGR peptide with tumor-penetrating motif for microPET imaging of CD13-positive tumor xenografts

Molecular Imaging and Preclinical Studies of Radiolabeled Long-Term RGD Peptides in U-87 MG Tumor-Bearing Mice

Dual Targeting of Integrin αvβ3 and VEGF Receptor Improves PET Imaging of Breast Cancer

Tumor-penetrating Peptide Irgd Conjugation Effectively Potentiates Intratumor T Cell Infiltration.

The Inhibition Effects of c (RGD) 2 Peptides on Proliferation in B16 Melanoma Cells and the Its Imaging and Biodistribution Study in Tumor-bearing Mice

Biodistribution in Healthy KM Mice and Micro PET/CT Imaging in U87MG Tumor-Bearing Nude Mice of a New 18F-Labeled Cyclic RGD Dimer

Radiolabeling of RGD peptide and preliminary biological evaluation in mice bearing U87MG tumors.

18F-Labeled Magnetic Nanoparticles for Monitoring Anti-Angiogenic Therapeutic Effects in Breast Cancer Xenografts.

Modification of erythrocytes by internalizing Arg-Gly-Asp (iRGD) in boosting the curative effect of radiotherapy for gastric carcinoma

18F Labeled RGD‐A7R Peptide for Dual Integrin and VEGF‐targeted Tumor Imaging in Mice Bearing U87MG Tumors

Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.

Synthesis, Preclinical Evaluation and Radiation Dosimetry of a Dual Targeting PET Tracer [68Ga]ga-Fapi-rgd

Preliminary Clinical Application of RGD-Containing Peptides as PET Radiotracers for Imaging Tumors

An Experimental Study On Targeted Therapy Of Radioiodinated Cyclic Crgd Peptide On Melanoma Bearing Mice

18F-FP-PEG2-β-Glu-RGD2: A Symmetric Integrin αvβ3-Targeting Radiotracer for Tumor PET Imaging

Peptidic Heterodimer-Based Radiotracer Targeting Fibroblast Activation Protein and Integrin Αvβ3.

Data from A Paradigm of Cancer Immunotherapy Based on 2-[<sup>18</sup>F]FDG and Anti–PD-L1 mAb Combination to Enhance the Antitumor Effect